NCT06965309 2026-02-12
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase NA Terminated
Clinical Trials
15 trialsNCT04226170 2025-09-11
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
DAS-MG, Inc
Phase 2 Terminated
NCT05132569 2025-09-09
URSA
Sanofi
Phase 3 Terminated
NCT04963270 2025-02-28
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Hoffmann-La Roche
Phase 3 Terminated
NCT05218096 2025-01-09
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03896295 2023-06-27
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02102594 2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2 Terminated
NCT03059888 2019-11-22
Trial of Orencia in Patients With Myasthenia Gravis
Johns Hopkins University
Phase EARLY_PHASE1 Terminated
NCT00727194 2019-09-24
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01268280 2019-09-24
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
Cytokinetics
Phase 2 Terminated
NCT01828294 2019-04-03
SIMM
St. Louis University
Phase 1 Terminated
NCT00424489 2018-08-31
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Phase 1 Terminated
NCT00995722 2017-06-02
EPITOME'
University of Miami
Phase 3 Terminated
NCT00004682 2015-03-25
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
FDA Office of Orphan Products Development
Phase NA Terminated